Skip to content
10-K

Annual Report

REGENOCELL THERAPEUTICS, INC.

0001213900-12-003016

← back to feed
Filed
May 25, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2011 · Mar 31, 2012 90.43M sh
Operating Cash Flow FY 2011 · Dec 31, 2011 −$317.46K
Operating Cash Flow FY 2011 · Dec 31, 2010 −$177.41K
Cash And Equivalents FY 2011 · Dec 31, 2011 $11.05K
Cash And Equivalents FY 2011 · Dec 31, 2010 $3.44K
Cash And Equivalents FY 2011 · Dec 31, 2009 $102.08K
Stockholders Equity FY 2011 · Dec 31, 2011 −$5.45M
Stockholders Equity FY 2011 · Dec 31, 2010 −$4.1M
Stockholders Equity FY 2011 · Dec 31, 2009 −$353.77K
Current Liabilities FY 2011 · Dec 31, 2011 $2.34M
Current Liabilities FY 2011 · Dec 31, 2010 $1.46M
Total Liabilities FY 2011 · Dec 31, 2011 $5.7M
Total Liabilities FY 2011 · Dec 31, 2010 $4.45M
Current Assets FY 2011 · Dec 31, 2011 $166.36K
Current Assets FY 2011 · Dec 31, 2010 $191.45K
Total Assets FY 2011 · Dec 31, 2011 $247.43K
Total Assets FY 2011 · Dec 31, 2010 $342.43K
Sga Expense FY 2011 · Dec 31, 2011 $364.14K
Sga Expense FY 2011 · Dec 31, 2010 $331.23K
Net Income FY 2011 · Dec 31, 2011 −$1.3M
Net Income FY 2011 · Dec 31, 2010 −$3.81M
Operating Income FY 2011 · Dec 31, 2011 −$862.87K
Operating Income FY 2011 · Dec 31, 2010 −$3.56M
Cost Of Revenue FY 2011 · Dec 31, 2011 $127.12K
Cost Of Revenue FY 2011 · Dec 31, 2010 $92.41K
Revenue FY 2011 · Dec 31, 2011 $865.02K
Revenue FY 2011 · Dec 31, 2010 $910.05K